Lineage Cell Therapeutics, Inc. Board of Directors

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Ms. Jill Ann Howe

Ms. Jill Ann Howe

CFO & Principal Financial and Accounting Officer

Mr. George A. Samuel III, J.D.

Mr. George A. Samuel III, J.D.

General Counsel & Company Secretary

Ms. Alexandra Hernandez

Ms. Alexandra Hernandez

Senior Director of Finance & Controller

Dr. Harold D. Waitz

Dr. Harold D. Waitz

Vice President of Regulatory Affairs & Quality Control

Ms. Ioana C. Hone

Ms. Ioana C. Hone

Director of Investor Relations

Dr. Charlotte Hubbert Ph.D.

Dr. Charlotte Hubbert Ph.D.

Vice President of Corporate Development

Mr. William Annett MBA

Mr. William Annett MBA

President & CEO of OncoCyte Corporation

Dr. Rami Skaliter Ph.D.

Dr. Rami Skaliter Ph.D.

Chief Executive Officer of Cell Cure Neurosciences

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.